NEW YORK (GenomeWeb News) — Investment bank UBS today downgraded Cepheid’s stock to ‘neutral’ from ‘buy.’
 
Cepheid’s shares have risen 135 percent since the start of the year and reached a new 52-week high yesterday when they reached $20.29. Shares closed at $20.17 that day.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.